Research programme: cancer therapeutics - Galapagos NV

Drug Profile

Research programme: cancer therapeutics - Galapagos NV

Alternative Names: '1790 - Galapagos NV; GLPG 1790; Triple-negative breast cancer therapy - Galapagos NV

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galapagos NV
  • Class Small molecules
  • Mechanism of Action EphA2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malignant melanoma
  • No development reported Breast cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer in Belgium (PO)
  • 18 Mar 2014 Pharmacodynamics and adverse events data from a preclinical trial in triple-negative Breast cancer released by Galapagos NV
  • 01 Jan 2014 Preclinical trials in Malignant melanoma in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top